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Effect of Senescence on Macrophage Polarization
and Angiogenesis
Dru S. Dace and Rajendra S. Apte

ABSTRACT
There is mounting evidence that as the immune system ages, a progressive deterioration in
normal function occurs. Termed immunosenescence, aging impacts both the innate and adaptive immune responses. This review discusses the age-related alterations in the innate immune system, with a specific focus on macrophages. The downstream effect of altered macrophage function on aberrant angiogenesis in the pathophysiology of age-related eye disease
is also discussed.

INTRODUCTION

I

consist of two immunological subsystems: the
innate immune response and the adaptive immune system. These two immune responses
function in a complicated interactive, cross-regulative, and synergistic fashion to protect the
host against foreign microbial attack, inhibit tumor development, promote wound healing,
and maintain homeostasis in several tissues.
The innate immune system encompasses a collection of host defenses that range from the
non-specific barrier function of epithelia to the
highly selective recognition of pathogens
through the use of germline-encoded receptors.
A common feature of innate immune system
components is a rapid and blunt response to
infection or tissue destruction.1 In contrast, the
adaptive immune system uses somatically rearranged antigen receptor genes to create receptors for virtually any antigen. Although
slower to respond, the adaptive immune system is more flexible and specific, and is able to
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combat infections that have evolved to evade
the innate immune response. The induction of
the adaptive immune response is dependent
upon the innate immune response, including
cytokine and chemokine secretion by innate
immune cells and antigen presentation by macrophages and dendritic cells (DC). The adaptive immune response can differentiate into a
Th1, Th2, or Th17 immune response, which is
defined by their cytokine secretion profile. Th1
immune responses are responsible for cell-mediated immunity (cytotoxic T lymphocytes),
while Th2 immune responses are responsible
for humoral immunity (antibody production).2
Th17 is a newly discovered arm of adaptive immune responses involved primarily in autoimmune diseases.3 Upon activation of the adaptive immune response, the innate immune
response can also be altered. For example, the
secretion of IFN- by Th1 cells can lead to the
further activation of innate immune cells,
whereas the secretion of immunosuppressive
cytokines such as interleukin-10 (IL-10) by regulatory T cells can downregulate innate im-
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mune responses. This cross-talk between the
innate and adaptive immune responses demonstrates the highly choreographed and regulated interplay of immune responses occurring
in the body. Both immune responses, however,
exhibit a markedly decreased capacity to function as the host ages. This leads to increased
susceptibility to infectious diseases, neoplasias,
and autoimmune diseases, and reduced responses to preventative vaccination. These
complex changes to the immune system over
time are collectively called immunosenescence.4

MACROPHAGES
Mononuclear phagocytes are of critical importance for host immune defenses. Monocytes
emigrate from blood vessels in response to antigenic stimuli and differentiate in the tissues
into either macrophages or dendritic cells.5
Macrophages are best known for initiating innate immune responses against microbes by
recognition of pathogen-associated molecular
patterns (PAMPs) through pattern-recognition
receptors (PRPs).6 It has been recently identified that macrophage populations are distinctly heterogeneous. Macrophage heterogeneity arises as macrophages differentiate
from monocyte precursors and is determined
by the genetic background, as well as by specific tissue-related and immune-related stimuli.5,7 More specifically, microbial antigens, tumor products, and cytokines produced by Th1,
Th2, or Th17 effector cells influence the heterogeneity and the state of activation of macrophage populations.8,9
Some researchers have broadly subdivided
heterogeneic macrophages into two subpopulations: M1 and M2 macrophages.10,11 According to this classification, M1 macrophages, or
“classically activated macrophages,” are
thought to be induced in a Th1-like cytokine
environment (IFN-, TNF-, GM-CSF) or upon
recognition of PAMPs (LPS, lipoproteins,
dsRNA) and endogenous “danger” signals.12
M1 macrophages typically produce high levels
of IL-12 and IL-23, low levels of IL-10, and are
strong promoters of Th1 immune responses.12
M1 macrophages also exert anti-proliferative
and cytotoxic activities toward tumor and vi-

rally infected cells, resulting partly from their
ability to secrete reactive oxygen species and
proinflammatory cytokines such as IL-, TNF, and IL-6.11–13 M1 macrophages are efficient
mediators of resistance against intracellular
parasites and tumors.10
Macrophages classified as M2, or “alternatively activated macrophages,” develop in the
presence of Th2 cytokines such as IL-4 and IL13, deactivating cytokines such as IL-10 and
TGF-, immune complexes, hormones, and
apoptotic cells.11,14 M2 macrophages promote
Th2 responses, have reduced levels of inflammatory cytokines, are IL-12low and IL-23low,
and secrete copious amounts of anti-inflammatory cytokines such as IL-10 and TGF-.12
Accordingly, M2 macrophages exert selective
immunosuppressive functions and inhibit T
cell proliferation.15,16 The presence of M2 macrophages in healthy individuals in the placenta,
lungs, and immune privileged sites, as well as
in chronic inflammatory diseases like rheumatoid arthritis, suggests that M2 macrophages
protect organs and surrounding tissues against
detrimental immune responses. M2 macrophages orchestrate encapsulation and containment of parasites, promote tissue repair, and
enhance tumor progression.10
Although macrophages have been classified
as having an M1 and M2 phenotype, macrophages are highly plastic and the tissue microenvironment can continuously modify their
function.17 It is also thought that condensing
the heterogeneity of macrophage populations
into two subdivisions may be an oversimplification. Gordon et al. have stated that this dual
classification “obscures important differences
in macrophage responses.”14 Also, gene array
analyses have shown that treatment of macrophages with different cytokines results in
unique functional profiles with remarkably
small overlap.18 We therefore refrain from classifying macrophages as M1 or M2 for the remainder of this review and focus more on macrophage function as a means of classifying
them.
Macrophages and angiogenesis
One of the earliest physiological responses to
tissue injury or infection is an increase in vas-
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cular permeability and blood flow to the affected area. This is initiated by regional vasodilation and enhanced angiogenesis to facilitate
wound healing. This increase in blood flow and
angiogenesis is largely achieved by factors produced by cells of the innate immune system,
primarily macrophages. Inflammatory products such as LPS bind to toll-like receptors
(TLR) on macrophages, resulting in the synthesis and release of vascular endothelial
growth factor (VEGF). This results in vasodilation, recruitment of CD31 endothelial progenitor cells, and angiogenesis.19,20 Also, the release of TNF- and IL-1 by macrophages
promotes blood vessel permeability and angiogenesis.21 In addition to inducing angiogenesis, macrophages have been shown to play
a central role in the remodeling of small conduit blood vessels into larger muscular arterioles.22 Tissue-macrophage release of matrix
metalloproteinases also appears to be required
for the extracellular matrix remodeling essential for effective angiogenesis to occur.23 CCR2deficient mice, which lack the necessary
chemokine receptor needed for macrophage
migration, have impaired blood vessel formation following experimental arterial occlusion.24
However, the formation of blood vessels is
not always beneficial as angiogenesis in some
cases can actually exacerbate a pre-existing disease phenotype. Within tumors, increased angiogenesis leads to accelerated tumor growth,
invasiveness, and metastasis. The role of tumor-associated macrophages (TAM) being either pro-angiogenic or anti-angiogenic seems
to depend on their polarization state, which is
influenced by cytokines present in the tissue
milieu.11,25,26 In the majority of cases, the tumor
microenvironment seems to polarize macrophages towards a pro-angiogenic phenotype,
resulting in TAMs to be associated with a “bad”
prognosis in most tumor models.27,28 Therapies
that target TAMs have been shown to be beneficial for reduction of tumor size and/or tumor rejection.29 However, not all TAMs support the growth of tumors, as there are multiple
accounts of macrophages being tumoricidal
and necessary for tumor rejection.30–32 This
again underscores the heterogeneity of macrophage populations and their influence on tumor growth or progression.
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Unbridled angiogenesis also plays a role in
the progression of diseases of aging. The proangiogenic cytokine VEGF, which is released
by macrophages, is likely to play a role in the
pathophysiology of arthritis, as mice with a target disruption of VEGF exhibited significantly
less joint swelling and inflammation than wildtype animals.33 Also, macrophages have been
implicated to promote abnormal blood vessel
growth in murine tissue injury models.34 In
atherosclerosis, macrophages have been implicated in stimulating angiogenesis in atherosclerotic plaques, further promoting inflammation and exacerbating disease.35
Effect of aging on macrophages
The effect of aging on the innate immune system seems to have a detrimental effect on the
health of elderly individuals. There is a significant decline in the ability to resist infectious
diseases and generate robust protective immune responses in the elderly. Morbidity due
to infectious diseases is high in this segment of
the population. There is a high incidence of infection with viral influenza, respiratory syncytial virus, and pneumococcal pneumonia in elderly individuals.36,37 Older individuals also
have an increased incidence of bacterial infections in the lungs, urinary tract, and skin. The
increased incidence of infections suggests possible defects in the ability of the innate immune
system to function normally as age increases.
Advanced age is associated with a breakdown
of the epithelial barriers of the skin, lung, and
gastrointestinal tract, enabling the invasion of
delicate mucosal tissues by pathogenic organisms. Also, aging seems to effect the normal
function of cells of the innate immune system,
including macrophages.
The effect of age on macrophages appears to
be multifaceted, affecting almost every aspect of
their normal cellular function. Macrophages
from old mice failed to lyse tumor targets and
produce nitric oxide at levels similar to young
mice.38 Also, Ding et al. found that macrophages
from old mice produced 50% less hydrogen peroxide and nitric oxide than young mice when
stimulated with a variety of agents, and that
macrophages from old mice were less responsive to IFN- even though surface expression of
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IFN- receptor was similar in old and young
mice.39 This decrease in IFN- signaling is indicated by reduced phosphorylation of mitogenactivated protein kinase (MAPK) and signal
transducer and activator of transcription-1
(STAT-1) in aged rodents.39,40 The effect of aging on macrophages is not restricted to mice, as
human monocytes from aged individuals are reported to display decreased cytotoxicity against
tumor cells in vitro after LPS stimulation, corresponding with decreased release of reactive oxygen and nitrogen intermediates.41,42
Macrophages may also actively contribute to
dysregulated immune function by their secretion of immunosuppressive substances, particularly prostaglandins (PGE). Macrophages
from old mice have higher PGE2 production
than those from young mice.43 This can affect
multiple cells of the immune system. PGE2 can
inhibit the function of DCs, the primary professional antigen presenting cell.44 Also, PGE2
directly inhibits T cells,43 and T cells from the
elderly may be more susceptible to such inhibition than T cells from the young.45 PGE2 also
suppresses IL-12 secretion, decreases surface
expression of MHC class II molecules on APCs,
and enhances IL-10 secretion, resulting in
downregulation of T cell function.46
Other functions of macrophages that are affected by age include antigen presentation and
phagocytosis. It has been reported that antigenpulsed macrophages from old mice stimulated
lower levels of T cell proliferation than macrophages from young mice.47,48 This may be due
to decreased expression of MHC class II levels
on aged macrophages,49 which contrasts to the
stable expression of MHC class II on young and
old DCs.50 Phagocytosis and clearance of infectious organisms are reduced with advanced
age.51–53 This may be due to the inability of
aged macrophages to recognize invading
pathogens, as aging macrophages demonstrate
decreased expression of TLRs.54 Alternatively,
aging macrophages may not be able to migrate
to the site of infections, as macrophage chemotactic response to complement-derived factors
is impaired in the elderly.55,56
Although the dysfunction of macrophages
may lead to increased susceptibility to microbial
infection, the continuing normal pro-inflammatory function of macrophages over time may
also lead to disease in the elderly. It has been
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suggested that the production of pro-inflammatory cytokines by macrophages and fibroblasts
is responsible for many age-associated diseases,
including diabetes, osteoporosis, and atherosclerosis.57,58 Termed inflamm-aging, it has been
hypothesized that, as a result of constant antigenic stimulation, the continual production of
inflammatory mediators could potentially trigger the onset of inflammatory diseases. This is
exemplified by elevated circulating levels of proinflammatory mediators, including IL-6, IL-1,
TNF-, and PGE2.59 Therefore, when it comes to
macrophage function in the elderly, a happy
medium is desirable for maintaining homeostasis. Too little macrophage activity leads to the
susceptibility of infection from microbial pathogens. Too much macrophage activity leads to a
pro-inflammatory state and an induction of autoimmune disease. Luckily, the plasticity of
macrophages allows their state of activity to be
virtually reversed.
The effect of age-associated factors on macrophage function is unknown and may be numerous. However, the plasticity of macrophages allows them to be a potential target for
therapy to reverse their phenotype and promote homeostasis.17 Oxidative stress is hypothesized to alter macrophage transcription
factors and nuclear receptors, altering their
ability to respond to inflammatory stimuli.60
Anti-oxidants may be a potential treatment
to reverse this cause of macrophage dysfunction, as they seem to improve macrophage inflammatory function.61,62 Also, neuroendocrine
factors and stress hormones have also been hypothesized to contribute to the immunosenescence and decreased macrophage function.63
An approach to promote normal macrophage
function in aged hosts may be to take a page
from cancer therapy, and target macrophages
with cytokines to promote the desired macrophage function.29 In addition to affecting macrophage function and activation, aging seems
to also affect macrophage polarization.64 The
plasticity of macrophages allows them to
switch their phenotype, and cytokines may be
the key to achieving a reversal of polarization.
Aging macrophages and ocular angiogenesis
Although there has been much work showing how age affects macrophage function
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against microbial pathogens and tumors, little
has been done to show that age affects macrophage influence on ocular angiogenesis. Immune vascular interactions can play an important role in regulating angiogenesis during
diseases of aging, such as neoplasias, arthritis,
and blinding eye disease.6,65,66 Our laboratory
has investigated the key role of macrophages
in inhibiting the growth of abnormal blood vessels in the eye in age-related macular degeneration (AMD), the leading cause of blindness in
people over 50 years of age.66,67 Blindness in
AMD occurs largely from the “wet” form of the
disease that is characterized by the development of abnormal blood vessels underneath
the retina, termed choroidal neovascularization
(CNV).68 We have demonstrated that mice that
lack IL-10 are significantly impaired in their
ability to generate CNV after laser-induced tissue injury to the eye.66 IL-10 inhibits macrophages from migrating to the site of tissue injury, implicating that macrophages are serving
in an anti-angiogenic manner in CNV.
Age may impact the polarization of macrophages towards an M1 or M2 phenotype. Polarization plays a pivotal role in determining
the effector function of macrophages.26 Macrophages stimulated in the presence of IFN-,
LPS, or GM-CSF produce high levels of cytokines such as IL-12, IL-23, IL-6, and TNF-,
with low levels of IL-10. This cytokine signature indicates an anti-angiogenic macrophage,
which also contributes to antibacterial and inflammatory immune functions. GM-CSF cultured macrophages inhibit CNV upon injection
into the eyes of mice at the time of tissue injury.66 In the presence of IL-10, IL-4, or IL-13,
macrophages become polarized to a pro-angiogenic phenotype, with a cytokine signature
of high levels of IL-10 and low levels of pro-inflammatory cytokines such as IL-6 and TNF-.
Interestingly, IL-10 production is elevated in
macrophages from aged rodents and humans.69,70 This suggests that as a macrophages
age, their polarization may shift from an anti-angiogenic, pro-inflammatory phenotype to a proangiogenic, anti-inflammatory phenotype. Also,
this suggests that one of the most important mediators of this phenotypic switch is IL-10.
As stated before, our laboratory has shown
that mice that lack IL-10 are significantly impaired in their ability to generate CNV after
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laser-induced tissue injury to the eye. This
work contrasts with the pro-angiogenic macrophage function that has been described in
other CNV studies. Espinosa-Heidmann et al.
and Sakurai et al. have shown that clodronateliposome depletion of macrophages led to less
CNV.34,71 However, the work of Espinosa-Heidmann and colleagues involved the depletion
of macrophages from old mice (16 months of
age). If macrophages from old mice (old macrophages) are skewed towards a pro-angiogeneic phenotype, then depletion of these macrophages may lead to reduced CNV. Our
hypothesis that macrophages are anti-angiogenic in the eye is supported by the work of
Lobov et al., who showed that macrophages are
responsible for the induction of apoptosis in the
vascular endothelial cells of the temporary
hyaloid vessels of the developing eye,72 and the
work of Ambati et al., in which mice lacking a
key macrophage recruitment chemokine (CCL2) developed spontaneous CNV.73 Taken together, this evidence suggests that there may
be angiogenic differences in macrophages from
young and old animals.
Additionally, as mentioned above, anti-oxidants reverse the age-associated dysfunction of
macrophages by improving their inflammatory
function.61,62 It has also been found that supplementation of anti-oxidants to patients suffering from AMD delayed the progression of
disease, including the development of CNV.74
This further supports the hypothesis that macrophages function in an anti-angiogenic role in
the eye, and that aging results in macrophage
dysfunction, specifically related to the development of ocular blood vessels.
Our laboratory has recently performed experiments to specifically examine the ability of
old macrophages to prevent neovascularization.75 In our model of laser-induced CNV, old
mice demonstrated significantly more neovascularization compared to young mice. This increased CNV seems to be due to the failure of
old macrophages to prevent angiogenesis, as
old macrophages injected into the eyes of
young mice did not prevent CNV as effectively
as when macrophages from young mice (young
macrophages) were injected into the eyes of
mice following laser-induced injury. We examined the cytokine profile of old macrophages in
the eye following laser-induced injury, and we
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FIG. 1. The effect of senescence on macrophage cytokine expression and angiogenesis. Macrophages from young
mice demonstrate increased levels of proinflammatory cytokines, including TNF-, IL-23, IL-12, and IL-6. This results
in an anti-angiogenic macrophage phenotype, leading to less choroidal neovascularization (CNV) following laser induced injury. Macrophages from old mice, however, demonstrate decreased levels of the same proinflammatory cytokines and increased levels of the immunosuppresive cytokine IL-10. These macrophages are skewed to an alternatively activated macrophage phenotype, resulting in increased CNV following laser-induced injury.

observed a significant downregulation of IL-12,
TNF-, and Fas ligand. These cytokines, however, were unaltered or upregulated in macrophages from young mice. Young macrophages
upregulated the proinflammatory cytokines IL6 and IL-23, whereas old macrophages did not.
Again, it seems that IL-10 is the key cytokine
in determining the phenotypic switch of macrophages. Examining the levels of IL-10 in the
eyes of young and old mice, IL-10 levels were
significantly higher in old animals.75 This suggests that the micromilieu in old mice might
create an environment that promotes the polarization of infiltrating macrophages to a proangiogenic phenotype. The effect of IL-10 on
macrophage polarization is further exemplified
when we treated young macrophages with IL-

10 and injected them into the eyes of laser-injured eyes; IL-10-treated macrophages failed to
inhibit CNV.75 This clearly highlights IL-10 as
a pro-angiogenic cytokine and that macrophages, in the presence of IL-10, do not demonstrate anti-angiogenic properties.
We also demonstrated the effect of aging on
macrophages and their ability to regulate
angiogenesis in vitro. Thioglycollate-induced
peritoneal macrophages were harvested and
assessed for their ability to inhibit the growth
and proliferation of vascular endothelial cells.
Macrophages from young and IL-10 deficient
animals significantly inhibited vascular endothelial cell proliferation, whereas macrophages
from old mice had no effect.75 This demonstrates a direct inability of senescent macro-
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phages to inhibit the growth of blood vessel
cells. The effect of aging on macrophage polarization and angiogenesis is summarized in
Figure 1.

SUMMARY
Aging results in the dysfunction of both the
innate and adaptive immune systems. Immunosenescence leads to increased susceptibility to infection and tumor formation and
inflammatory diseases of aging such as osteoporosis and diabetes. Macrophages seem particularly susceptible to immunosenescence,
and over time seem to polarize towards a proangiogeneic phenotype. This can result in the
formation of unwarranted blood vessels and
exacerbation of disease processes, such as
AMD. Fortunately, the plasticity of macrophages renders them ideal targets for therapy,
as cytokine/antibody treatment and gene therapy may result in a reversal of disease phenotype.
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